Quick Facts

• Support for Exocrine Pancreatic Insufficiency (EPI): Panzytrat 25000 is used to provide enzyme replacement in individuals with pancreatic exocrine insufficiency.
• Use in Specific Conditions: This therapy is indicated for managing EPI resulting from conditions such as cystic fibrosis, chronic pancreatitis, and certain surgical procedures like pancreatectomy or gastrointestinal bypass surgery.
• Aids Nutrient Processing: The use of this treatment assists the body in processing fats, proteins, and carbohydrates from food intake.

Panzytrat 25000 is a pancreatic enzyme replacement therapy prescribed to manage Exocrine Pancreatic Insufficiency (EPI). EPI is a digestive condition where the pancreas does not release sufficient enzymes to process food, potentially leading to nutrient malabsorption.

This medication is indicated for use across a range of underlying conditions that can result in EPI. These conditions generally include cystic fibrosis, chronic inflammation of the pancreas (chronic pancreatitis), and states following specific surgical interventions such as the removal of the pancreas (pancreatectomy) or gastrointestinal bypass procedures. Additionally, it may be used to address EPI associated with ductal obstruction.

The therapeutic goal of Panzytrat 25000 is to provide the necessary enzymes—lipase, amylase, and protease—that assist in the processing of dietary fats, starches, and proteins within the digestive tract. This assistance with digestion may support improved nutritional status and may help manage associated symptoms of nutrient malabsorption. Pancrelipase-containing products are established as a standard care for these indications. This treatment is intended to be used only under the guidance of a healthcare professional.

This medicine is generally approved for use in adults and children who require pancreatic enzyme replacement therapy. However, official regulatory information establishes specific conditions that strictly prohibit its use or require special caution.

Populations That Must Not Use Panzytrat 25000 (Contraindicated)

• Individuals with acute pancreatitis should not take this medicine.
• Patients with a known hypersensitivity or allergy to pork proteins or pig products (the source of the enzymes), or any other ingredient listed in the medicine’s formula.

Populations With Restricted Use or Requiring Caution

• Pregnancy and Breastfeeding: Use during pregnancy, planning for pregnancy, or breastfeeding requires a discussion with a healthcare provider to assess the risks and benefits.
• Pediatric Patients: Use in children is established but high-dose therapy must be monitored closely. Doses exceeding a maximum limit, such as 10,000 units of lipase per kilogram of body weight per day, are associated with a potential risk of fibrosing colonopathy (a rare bowel condition) and require caution and regular medical review.

Interactions with other medicines and products — Official Regulatory Information

The official interaction profile of Panzytrat 25000 is defined by luminal effects, as the drug is not systemically absorbed. Regulatory documents impose specific constraints on co-administration with other substances:

Interaction-Related Restrictions

• Alpha-Glucosidase Inhibitors: Co-administration with medicines like Acarbose is formally restricted. Pancreatin may reduce the therapeutic effect of alpha-glucosidase inhibitors.
• Antacids (e.g., Magnesium/Calcium): These substances may reduce the therapeutic effect of Pancreatin by causing the premature dissolution of the enteric coating. A timing separation rule is mandated: if Antacids must be taken, they should be administered at least one hour before Panzytrat 25000.
• Exposure Modification: Pancreatin may diminish the gastrointestinal absorption of co-administered Iron preparations and Folic acid when used over long periods.

Other Documented Interactions

• Cimetidine: The H2 receptor antagonist Cimetidine is officially documented as potentially potentiating the effect of Pancreatin.
• High-Fiber Diet: Regulatory context includes a note that a diet rich in fiber may interfere with the enzyme activity of Pancreatin.

The regulatory documents define the interaction structure as centered on these localized luminal and absorption-altering constraints, without documenting systemic CYP-mediated or transporter-based interactions.

Panzytrat 25000 delivers pancrelipase, an enzyme mixture of lipase, amylase, and protease, to the gastrointestinal lumen. The microtablets possess an enteric coating that resists the acidic environment of the stomach, protecting the enzyme proteins from acid-mediated denaturation and inactivation.

Upon reaching the proximal small intestine (duodenum), the local increase in pH above 5.5 triggers the dissolution of the enteric coating. This event releases the active enzymes into the intestinal chyme, where they operate locally as catalysts to facilitate digestive hydrolysis. The biological targets are dietary triglycerides, complex carbohydrates (starches), and proteins within the food matrix.

Specifically, lipase catalyzes the hydrolysis of triglycerides into monoglycerides and free fatty acids. Amylase mediates the breakdown of starch into smaller oligosaccharides and disaccharides via cleavage of alpha-1,4-glycosidic bonds. Protease (including trypsin and chymotrypsin) catalyzes the hydrolysis of proteins into oligopeptides and amino acids. These actions increase the concentration of absorbable macro-molecules in the intestinal lumen, modulating the systemic availability of nutrients.

Official Administration Guidelines

Panzytrat 25000 is an oral medication and must be taken during or immediately after all meals and snacks to ensure the active enzymes mix with the food bolus. The dose, measured in lipase units, is highly individualized and is determined by a healthcare professional based on body weight, severity of the condition, and the fat content of the diet.

Labeled Dosing Regimens (Lipase Units/kg/Meal)

The maximum total daily dose should generally not exceed 10,000 lipase units/kg of body weight. Half of the prescribed dose for a main meal should be administered with each snack. The total daily dosing should reflect approximately three meals plus two or three snacks per day.

Administration Instructions and Restrictions

Do not crush or chew the hard capsules or their contents, as this action disrupts the gastro-resistant coating and renders the enzymes ineffective. Capsules must be swallowed whole with sufficient fluid (water or juice) to ensure complete ingestion and prevent irritation of the oral mucosa.

For patients unable to swallow the capsule, the entire contents may be opened and sprinkled onto a small amount of acidic soft food (such as applesauce or yogurt) with a pH less than 5.5. The mixture must be consumed immediately and not stored. For infants (12 months and younger), a specific dosing scheme of 2,000 to 4,000 lipase units per 120 mL of formula or breastfeeding applies, and the capsule contents must not be mixed directly into a bottle of breast milk or formula. Therapy is intended for long-term use and requires gradual dose titration.

Research Evidence for Panzytrat 25000: Overview of Studies

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI)

The clinical evaluation of Pancreatin therapy was studied for people diagnosed with Exocrine Pancreatic Insufficiency (EPI). Research examined measurements related to the ability to break down and absorb nutrients. The foundational research involves short-term, randomized, placebo-controlled trials. These studies were designed to monitor objective nutrient absorption biomarkers, specifically the Coefficient of Fat Absorption (CFA), an objective biomarker used to measure fat processing. These results contribute to the broader evidence landscape related to malabsorption.

Studies reported that measurements of these objective biomarkers—CFA and the Coefficient of Nitrogen Absorption (CNA)—showed patterns related to the active therapy compared to a placebo. Beyond these objective laboratory measures, other studies examined patient-reported experiences, which tracked outcomes related to physical discomfort, such as changes in the frequency and weight of stool.

Evidence in Patients with Chronic Pancreatitis and Post-Surgical States

Research examined the use of this therapy in adults with EPI where the underlying cause was Chronic Pancreatitis or following pancreatic surgical procedures. Observational studies explored daily-life functioning and tracked outcomes related to systemic or functional imbalance over intermediate periods. While objective measurements like CFA was observed in some studies to show patterns related to the therapy, the evidence related to outcomes related to physical discomfort, particularly abdominal pain, has been reported as mixed.

Key Research Gaps and Areas of Uncertainty

The research contributes to the broader evidence landscape, but the scientific literature explicitly outlines several areas where data are still emerging and certainty remains low. One key research limitation is the heterogeneity among studies, meaning that trial designs, patient populations, and primary outcomes are not always directly comparable across the board. Furthermore, while the short-term findings on absorption are well-described, the long-term effects are not fully established on chronic nutritional status, such as bone density. Data for certain groups, such as pregnant populations or those with specific comorbidities, also remain insufficient.

Common questions about Panzytrat 25000 (FAQ)

Q: What is Panzytrat 25000 used for?

According to official product information, Panzytrat 25000 is a pancreatic enzyme replacement therapy. It is used to treat exocrine pancreatic insufficiency, which is a condition where the pancreas does not produce enough enzymes to digest food properly. This condition is often associated with digestive disorders such as cystic fibrosis or chronic pancreatitis.

Q: How do the enzymes in Panzytrat 25000 work?

Panzytrat 25000 contains a mix of porcine pancreatic enzymes, primarily lipase, amylase, and protease. Regulatory documents indicate that these ingredients are necessary to help the body break down fats, starches, and proteins in the consumed food. The medicine is designed to act locally within the small intestine to assist the digestive process.

Q: What happens if I miss a dose of Panzytrat 25000?

Official product information states that if a dose is missed, individuals should resume their usual schedule with the next planned meal or snack. Regulatory labeling generally advises against taking a double dose to compensate for a missed one. The goal is to maintain the consistency of the prescribed treatment schedule.

Q: Can I open the capsules of Panzytrat 25000 and mix the contents with food?

Studies and official information indicate that the capsules should generally be swallowed whole. However, if there is difficulty swallowing, the capsules can be opened, and the contents (pellets) may be mixed with a small amount of specific, soft, acidic foods. Regulatory documents state that when mixed with food, the mixture is intended to be consumed right away, and the pellets should not be chewed.

Q: Does Panzytrat 25000 need to be stored in a special way?

According to the official product information, Panzytrat 25000 should be stored at room temperature, which is below 25°C (77°F). It is important that the medicine remains in the original container to protect it from moisture. As with all medicines, it is intended to be stored safely away from children.

Storage and Disposal of Panzytrat 25000

The storage of Panzytrat 25000 must strictly follow the conditions defined in the official regulatory labeling.

Storage Requirements

The capsules must be stored at a temperature that stays below 25°C (77°F). It is mandatory to keep the bottle tightly closed in the original container and in a dry place to protect the contents from moisture. The product should not be stored in environments prone to high heat or dampness, such as a bathroom or a closed vehicle.

Stability and Child Safety

Once the container is first opened, the capsules must be used within 3 months to maintain product stability. For safety, Panzytrat 25000 must be kept out of the sight and reach of children.

Disposal Instructions

To dispose of expired or unused Panzytrat 25000, you must ask a pharmacist for guidance on the proper disposal procedure. The product is not classified as an additional environmental hazard during disposal.